The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Ben Haynor - A.G.P./Alliance Global Partners - Analyst
: Good day, gentlemen. Thanks for taking the questions. First of all for me, I just wanted to touch on the Stratasys agreement. I'm not entirely sure
on how -- or whether the Stratasys printed implants are going to be the ones used in the second half -- or second large animal study that's second
half of this year. Can you provide some clarification on that?
Question: Ben Haynor - A.G.P./Alliance Global Partners - Analyst
: Okay, great. So the optimization will be complete before that occurs. And then remind me, could the -- the second large animal study, could that
be used for the registration study to submit to the FDA?
Question: Ben Haynor - A.G.P./Alliance Global Partners - Analyst
: Okay, great. And then just -- if you could tell me how meaningful the cross-promotion portion of the agreement with Stratasys is -- I mean, it seems
to me that having a turnkey offering from Stratasys to bring to their customers would be fairly important. I'm just curious about how you see that
playing out.
Question: Ben Haynor - A.G.P./Alliance Global Partners - Analyst
: Okay, great. That's helpful. And then when should we expect to hear more about the third-generation photocurable soft tissue filler? My recollection
was that you had submitted some data to AbbVie. Just curious on that.
Question: Ben Haynor - A.G.P./Alliance Global Partners - Analyst
: Okay, got it. And then lastly for me, I think -- well, I guess I don't recall you mentioning body contouring applications for the photocurable product.
Could you talk a little bit more about those and maybe the obvious applications that you see there?
Question: Ben Haynor - A.G.P./Alliance Global Partners - Analyst
: Okay. Thank you. So I guess what would -- outside of facial, what would be an example application? I mean, is it -- if I don't like the crease in my
armpit, do I get that filled? Or what are the more non-facial applications?
Question: Ben Haynor - A.G.P./Alliance Global Partners - Analyst
: Okay, got it. Well, thanks for taking the questions, gentlemen. This is definitely helpful.
Question: Swayampakula Ramakanth - H.C. Wainwright & Co., LLC - Analyst
: Thank you. I have a couple of questions. The first one is on the research program, the gut-on-a-chip program. So with your relationship with the
universities there, what are you planning to show, at least in '23, to see if you can get outside partnerships so that you can make this a commercializable
product?
Question: Swayampakula Ramakanth - H.C. Wainwright & Co., LLC - Analyst
: Fantastic. And then on those -- on the inks, on the bioinks, the different [buy] that you're talking about that you want to convert in the commercial
portfolio. So with the one which is in the market now, the 3D 50L, what are you learning in terms of people using it? And how do you see that
growing in terms of revenues, not only this product, but also the later projects that you're looking at, the 3D 50 and the 3D 90?
Question: Swayampakula Ramakanth - H.C. Wainwright & Co., LLC - Analyst
: Okay, very good. That's all I have for you folks. Thank you.
| 
